Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
7
|
| gptkbp:bfsParent |
gptkb:Zimhi
gptkb:Narcan |
| gptkbp:activities |
opioid receptor antagonist
|
| gptkbp:appointed_by |
gptkb:fragrance
injection |
| gptkbp:approves |
gptkb:1971
gptkb:FDA |
| gptkbp:associated_with |
public health initiatives
harm reduction strategies opioid use disorder treatment |
| gptkbp:availability |
widely available in pharmacies
available in emergency kits distributed by harm reduction programs |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:duration |
30 to 90 minutes
|
| gptkbp:form |
gptkb:fragrance
auto-injector injectable solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Naloxone
|
| gptkbp:impact |
reduces opioid overdose deaths
|
| gptkbp:ingredients |
C17 H21 N3 O5 S
|
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_effective_against |
rapid onset of action
non-opioid overdoses alcohol overdose benzodiazepine overdose |
| gptkbp:is_used_by |
gptkb:hospital
emergency responders bystanders |
| gptkbp:is_used_for |
opioid overdose
|
| gptkbp:legal_issue |
over-the-counter in some regions
prescription medication |
| gptkbp:manager |
intravenous
subcutaneous intramuscular |
| gptkbp:price |
varies by region
often covered by insurance available for free in some programs |
| gptkbp:public_awareness |
school programs
community training programs increased awareness campaigns |
| gptkbp:research_focus |
addiction treatment
emergency medicine opioid crisis |
| gptkbp:side_effect |
dizziness
headache nausea vomiting withdrawal symptoms sedation respiratory depression opioid effects |
| gptkbp:suitable_for |
gptkb:CDC
gptkb:WHO |
| gptkbp:traded_on |
gptkb:Narcan
|
| gptkbp:training |
for laypersons
|
| gptkbp:type_of |
357-08-4
|